Aldosterone induced vascular elastin production
View Patent ↗Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
1. A method of treating cardiac dysfunction in a subject with a post-infarct heart comprising:
administering an effective amount of aldosterone and an effective amount of spironolactone to said subject.
2. The method of claim 1 , wherein the aldosterone and the spironolactone are administered by a method selected from the group consisting of local administration and systemic administration.
3. The method of claim 1 , wherein the aldosterone and the spironolactone are administered by a mode selected from the group consisting of topical, parenteral, plural infusion, pericardial infusion, subcutaneous, intravenous, intraperitoneal, transdermal, oral, buccal, inhalation, depot injection, and implantation.
4. The method of claim 1 , wherein the aldosterone and the spironolactone affect the cardiac fibroblasts in a mineralocorticoid receptor independent manner.
5. The method of claim 1 , wherein the aldosterone and the spironolactone are administered simultaneously.
6. The method of claim 1 , wherein the spironolactone is administered prior to the aldosterone.
7. A method of improving the ejection fraction in a post-infarct heart of a subject comprising:
administering an effective amount of aldosterone and an effective amount of spironolactone to said subject.
8. The method of claim 7 , wherein the aldosterone and the spironolactone are administered by a method selected from the group consisting of local administration and systemic administration.
9. The method of claim 7 , wherein the aldosterone and the spironolactone are administered by a mode selected from the group consisting of topical, parenteral, plural infusion, pericardial infusion, subcutaneous, intravenous, intraperitoneal, transdermal, oral, buccal, inhalation, depot injection, and implantation.
10. The method of claim 7 , wherein the aldosterone and the spironolactone affect the cardiac fibroblasts in a mineralocorticoid receptor independent manner.
11. The method of claim 7 , wherein the aldosterone and the spironolactone are administered simultaneously.
12. The method of claim 7 , wherein the spironolactone is administered prior to the aldosterone.